Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...